Hospital Ruber Internacional

The trials here

What the 36 trials at this site are about, from their registry records.

Conditions

• Epilepsy16 trials
• Metastatic breast cancer5 trials
• Lung cancer4 trials
• Parkinson disease4 trials
• Prostate cancer4 trials
• Colorectal cancer2 trials
• Melanoma2 trials
• Narcolepsy2 trials
• Alzheimer disease1 trial
• Endometrial cancer1 trial
• Familial hypercholesterolaemia1 trial
• Mitochondrial disease1 trial
• and 2 more

Phase

• Phase 316 trials
• Phase 27 trials
• Phase 1/24 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 41 trial

Status

• Completed12 trials
• Active, not recruiting8 trials
• Recruiting8 trials
• Not yet recruiting5 trials
• Terminated2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Biohaven Therapeutics Ltd.3 trials
• Longboard Pharmaceuticals3 trials
• Xenon Pharmaceuticals Inc.3 trials
• AbbVie1 trial
• Bial R&D Investments, S.A.1 trial
• and 25 more

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

  NCT07493265· Phase 2· Eisai Inc.· Source

• Recruiting

  Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

  2025-521562-95-00· Phase 3· Mabxience Research S.L.· Source

• Recruiting

  A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

  NCT07227857· Phase 1/2· Institut de Recherches Internationales Servier· Source

  Contact: Antonio Gil-Nagel Rein, Dr

• Not yet recruiting

  AI-based Progression and Medication Response Prediction Study in Parkinson's Disease

  NCT07189468· University Hospital, Toulouse· Source

  Contact: Monica Kurtis, MD

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Enrolling by invitation

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

  NCT06908226· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

  NCT06719141· Phase 3· Longboard Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

  NCT06660394· Phase 3· Longboard Pharmaceuticals· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

  NCT06392009· Phase 1/2· GRIN Therapeutics, Inc.· Source

• Recruiting

  Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)

  NCT07403266· Phase 3· Oils4Cure· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Not yet recruiting

  Phenotyping and Identification of Biological Markers in STXBP1 Encephalopathy

  NCT06356233· Fundación Iniciativa para las Neurociencias (FINCE)· Source

  Contact: Alvaro Beltran Corbellini, MD

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624

  NCT05781217· Phase 3· Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic· Source

  Contact: Aurora Rodríguez, MD

• Recruiting

  Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence after surgery

  2024-517666-41-00· Phase 3· Instituto De Investigacion En Oncología Radioterapica FEOR· Source

• Active, not recruiting

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· Phase 3· Celcuity Inc· Source

• Recruiting

  The Impact of Radiotherapy on Oligometastatic Cancer

  NCT05933876· Institut Investigacio Sanitaria Pere Virgili· Source

  Contact: Aurora Rodríguez

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Xenon Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy6 recruiting
• Prostate cancer3 recruiting
• Lung cancer2 recruiting
• Parkinson disease2 recruiting
• Colorectal cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Narcolepsy1 recruiting

Closed trials

• Completed

  A Trial to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy.

  2025-523503-30-00· Phase 2· Eisai Limited· Source

• Completed

  A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

  NCT05604170· Phase 3· Marinus Pharmaceuticals Inc.· Source

• Completed

  Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

  NCT05771428· Phase 2· AbbVie· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Completed

  An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s disease

  NCT05543252· Phase 2· UCB Biopharma· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes

  NCT05232630· Phase 4· Hospital Ruber Internacional· Source

• Completed

  A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

  NCT05218655· Phase 3· PTC Therapeutics· Source

• Terminated

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Phase 1/2· Genmab· Source

• Completed

  Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

  NCT04770337· Neuroelectrics Corporation· Source

• Terminated

  Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

  NCT04869943· Phase 3· Veru Inc.· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  MGD019 DART® Protein in Unresectable/Metastatic Cancer

  NCT03761017· Phase 1· MacroGenics· Source

• Completed

  Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

  NCT03310957· Phase 1/2· Seagen Inc.· Source